J. Stingl

发表

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

K. Sangkuhl, T. Klein, T. Klein, 2015, Clinical pharmacology and therapeutics.

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

J. Brockmöller, R. Viviani, J. Stingl, 2013, Molecular Psychiatry.

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

J J Swen, K. Sangkuhl, C. Thorn, 2013, Clinical pharmacology and therapeutics.

The relationship of weather with daily physical activity and the time spent out of home in older adults from Germany – the ActiFE study

J. Klenk, D. Rothenbacher, M. Denkinger, 2022, European Review of Aging and Physical Activity.

Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs

J. Brockmöller, J. Stingl, 2011, Clinical pharmacology and therapeutics.

Metabolite profiling in identifying metabolic biomarkers in older people with late-onset type 2 diabetes mellitus

J. Klenk, J. Steinacker, G. Nagel, 2017, Scientific Reports.

Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol

J. Lötsch, J. Brockmöller, M. Tzvetkov, 2011, Clinical pharmacology and therapeutics.

Association of lung function with overall mortality is independent of inflammatory, cardiac, and functional biomarkers in older adults: the ActiFE-study

J. Klenk, D. Rothenbacher, G. Weinmayr, 2020, Scientific Reports.

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

E. Corruble, R. Lanzenberger, J. Meyer, 2021, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

J. Brockmöller, J. Stingl, R. Viviani, 2014, Pharmacology & therapeutics.

Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

K. Sangkuhl, C. Thorn, C. Thorn, 2013 .

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

M O Karlsson, R M Turner, C H van der Wouden, 2017, Clinical pharmacology and therapeutics.

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

K. Sangkuhl, T. Klein, T. Skaar, 2017, Clinical pharmacology and therapeutics.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

M. Pirmohamed, A. Cambon-Thomsen, M. Ingelman-Sundberg, 2017, Clinical pharmacology and therapy.

[Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].

J. Brockmöller, J. Stingl, 2013, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

CYP2D6 in the Brain: Impact on Suicidality

R. Viviani, J. Stingl, J C Stingl, 2011, Clinical pharmacology and therapeutics.